Edition:
United States

Boston Scientific Corp (BSX)

BSX on New York Consolidated

27.58USD
25 Jul 2017
Change (% chg)

-- (--)
Prev Close
$27.58
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,533,373
52-wk High
$28.51
52-wk Low
$19.67

Latest Key Developments (Source: Significant Developments)

Boston Scientific outlines strategy for sustained growth at 2017 investor day
Tuesday, 27 Jun 2017 07:30am EDT 

June 27 (Reuters) - Boston Scientific Corp :Boston Scientific outlines strategy for sustained growth at 2017 investor day.Continues to expect to launch Lotus Edge valve system in Europe and submit U.S. pre-market approval submission in Q4 of 2017.Company expects to introduce vercise dbs system in U.S. by early 2018, pending regulatory approval.Goal is to achieve an organic revenue compound annual growth rate for 2018-2020 of six to eight percent.Goal is to achieve consistent double-digit adjusted EPS growth for 2018-2020.Five-year growth strategy intended to help reach a 25 percent adjusted operating margin in 2017 and 28 percent in 2020.  Full Article

Boston Scientific receives CE mark for Vercise Gevia deep brain stimulation system
Tuesday, 6 Jun 2017 06:30am EDT 

June 6 (Reuters) - Boston Scientific Corp ::Boston Scientific receives CE mark for Vercise™ Gevia™ deep brain stimulation system.Boston Scientific - ‍approval expands Vercise directional portfolio which is composed of Vercise primary cell, Vercise Gevia platforms.  Full Article

Boston Scientific announces positive results from the Reprise III clinical trial
Tuesday, 16 May 2017 06:47am EDT 

May 16 (Reuters) - Boston Scientific Corp :The Boston Scientific LOTUS™ valve system demonstrated superior efficacy to Corevalve® in global reprise III trial at one year.Boston Scientific Corp says LOTUS valve system also demonstrated non-inferiority to corevalve platform for primary safety endpoint.Boston Scientific - secondary endpoint demonstrated LOTUS valve system had lower rates of moderate to severe pvl occurrences compared to corevalve platform.Boston Scientific Corp - LOTUS valve system showed superiority over corevalve tavi system platform for primary effectiveness endpoint.  Full Article

Boston Scientific closes Symetis acquisition
Tuesday, 16 May 2017 01:15am EDT 

May 16 (Reuters) - Boston Scientific Corp ::Boston Scientific closes Symetis acquisition.To immediately begin selling Acurate TA and Acurate Neo/TF valve systems in Europe and other geographies outside of U.S..  Full Article

Boston Scientific announces results of study evaluating patients implanted with S-ICD System
Thursday, 11 May 2017 01:02pm EDT 

May 11 (Reuters) - Boston Scientific Corp ::Announced results from U.S. post-market approval study evaluating 'real-world' patients implanted with S-ICD System.Acute results for S-ICD System show therapy effectively terminated life-threatening heart arrhythmias in 98.7% evaluated patients.S-ICD System analysis also validated low complication rates, with a complication-free rate of 96.2 percent at 30 days post-procedure.  Full Article

Boston Scientific receives FDA approval for resonate family of high-voltage devices
Tuesday, 9 May 2017 06:30am EDT 

May 9 (Reuters) - Boston Scientific Corp : :Boston Scientific receives U.S. FDA approval for resonate™ family of high-voltage devices.Boston Scientific-FDA approval for resonate family of implantable cardioverter defibrillator and cardiac resynchronization therapy defibrillator systems.  Full Article

Boston Scientific reports Q1 GAAP EPS $0.21
Thursday, 27 Apr 2017 06:30am EDT 

April 27 (Reuters) - Boston Scientific Corp :Boston Scientific announces results for first quarter 2017.Q1 GAAP earnings per share $0.21.Sees FY 2017 revenue $8.8 billion to $8.9 billion.Q1 sales $2.16 billion.Sees FY 2017 GAAP earnings per share $0.81 to $0.86.Sees Q2 2017 GAAP earnings per share $0.18 to $0.21.Sees Q2 2017 sales $2.185 billion to $2.215 billion.Q1 adjusted earnings per share $0.29.Q1 interventional cardiology worldwide sales $605 million versus $560 million.Qtrly cardiac rhythm management worldwide sales $463 million versus. $433 million last year.Q1 earnings per share view $0.30, revenue view $2.08 billion -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $1.24, revenue view $8.77 billion -- Thomson Reuters I/B/E/S.Q2 earnings per share view $0.31, revenue view $2.21 billion -- Thomson Reuters I/B/E/S.  Full Article

Boston Scientific initiates global study to assess sudden cardiac arrest prevention therapy
Tuesday, 18 Apr 2017 04:15pm EDT 

April 18 (Reuters) - Boston Scientific Corp ::Boston Scientific initiates global study to assess sudden cardiac arrest prevention therapy in patients with diabetes who have previously experienced a heart attack.Boston Scientific - emblem mri s-icd system has been accepted for parallel review for new indication by fda, centers for medicare & medicaid services.Boston Scientific Corp- organizations will concurrently review madit s-icd trial data as well as other relevant information to determine fda approval.  Full Article

Boston Scientific CEO Michael Mahoney's FY 2016 total compensation was $12 mln vs $11.6 mln in FY 2015
Tuesday, 28 Mar 2017 05:31pm EDT 

Boston Scientific Corp :CEO Michael Mahoney's FY 2016 total compensation was $12.0 million versus $11.6 million in FY 2015 - sec filing.  Full Article

German patent court issues initial decision
Thursday, 9 Mar 2017 06:35am EST 

Edwards Lifesciences Corp - : District court in Germany ruled that Boston Scientific's lotus valve infringes one of co's patents for transcatheter aortic valves . Edwards is not updating its 2017 financial guidance . Does not presently anticipate disruption to supply of sapien 3 valves to patients . Court also ruled Edwards Sapien 3 valve infringes two of Boston Scientific's patents for outer seals of transcatheter heart valves .Will promptly request an appeal.  Full Article